


Committee on Energy and Commerce
 U.S. House of Representatives Witness
 Disclosure Requirement- "Truth in Testimony"
 Required by House Rule XI, Clause 2(g)

1. Your Name: Dr. Jonathan Niloff		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
3. Are you testifying on behalf of an entity that is not a government entity?	Yes X	No
4. Other than yourself, please list which entity or entities you are representing: McKesson Corporation		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that YOU or the entity YOU represent have received on or after October 1, 2011: Please see attachment.		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: Vice President, Chief Medical Officer, McKesson Connected Care & Analytics		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No X
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: None		
9. Please attach your curriculum vitae to your completed disclosure form.		

Signature



Date:

July 14, 2014

Response to Question 5:

Vaccines for Children Program Distributor (CDC)

Defense Health Agency: Medical Home Secure Messaging (Department of Defense)

TriCare: Mail Order Pharmaceutical (Department of Defense)

TriCare: Nurse Advice Services (Department of Defense)

Picture Archiving and Communications System for Imaging (Department of Defense)

Navy: Camp Pendleton Radiology Solutions (Department of Defense)

Navy: Camp Pendleton Cardiology Solutions (Department of Defense)

USAF: CCD PHR Integration (Department of Defense)

Pharmaceutical Prime Vendor (Department of Veterans Affairs)

VISN 5 – Radiology Solutions (Department of Veterans Affairs)

Medical Supplies (HHS)

CURRICULUM VITAE

JONATHAN M. NILOFF

Revised July 2014

Name: Jonathan Mitchell Niloff, M.D.

Home Address:

[REDACTED]
[REDACTED]

Place of Birth: Montreal, Quebec, Canada

Citizenship: United States of America

Current Position: Vice President and Chief Medical Officer, McKesson Connected Care & Analytics

Education:

1998	Boston University (High Honors)	MBA
1978	McGill University	M.D., C.M.
1973 - 1974	McGill University	Pre-med
1971 - 1973	Johns Hopkins University	Pre-med

Postdoctoral Training:

1983 - 1985	Fellow, National Cancer Cytology Center
1982 - 1984	Fellow in Gynecologic Oncology, Brigham and Women's Hospital, Boston
1979 - 1982	Resident in Obstetrics & Gynecology, Brigham and Women's Hospital, Boston
1978 - 1979	Intern in Surgery, McGill University Program, Jewish General Hospital, Montreal

Licensure and Certification:

1987	Certification of Special Qualification in Gynecologic Oncology, The American Board of Obstetrics and Gynecology
1985	The American Board of Obstetrics and Gynecology, Diplomat
1982	Certification Examination in Obstetrics and Gynecology, Corporation Professionnelle des Medecins du Quebec
1982	Specialist Certificate, Obstetrics and Gynecology, The Royal College of Surgeons of Canada
1981	Massachusetts Board of Registration in Medicine
1979	National Board of Medical Examiners, Diplomat

Academic Appointments:

1990 - 2011	Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
1989 - 1990	Assistant Clinical Professor of Surgery, Harvard Medical School
1986 - 1989	Assistant Professor of Surgery, Harvard Medical School
1985 - 1986	Assistant Professor of Obstetrics and Gynecology, Harvard Medical School
1985 - 1986	Tutor in Medical Sciences, Harvard Medical School
1982 - 1985	Instructor in Obstetrics and Gynecology, Harvard Medical School
1979 - 1982	Clinical Fellow in Obstetrics and Gynecology, Harvard Medical School

Hospital Appointments:

2008 - 2011	Honorary Staff, Beth Israel Deaconess Medical Center, Boston, MA
1994 - 2005	Attending Staff, Metrowest Medical Center, Framingham, MA
1988 - 1996	Consulting Staff, Mount Auburn Hospital, Cambridge, MA
1987 - 1996	Courtesy Staff, Faulkner Hospital, Boston, MA
1986 - 2008	Senior Obstetrician-Gynecologist, Beth Israel Hospital, Boston, MA
1986 - 1990	New England Deaconess Hospital, Boston, MA
1985 - 1986	Courtesy Staff, HCHP Hospital, Boston, MA
1984 - 2006	Assistant Physician, Dana-Farber Cancer Institute, Boston, MA
1984 - 1992	Associate Obstetrician and Gynecologist, Brigham and Women's Hospital, Boston, MA
1982 - 1984	Clinical Fellow in Gynecologic Oncology, Dana-Farber Institute, Boston, MA

Other Professional Positions and Major Visiting Appointments:

1997	Visiting Professor, Department of Obstetrics and Gynecology, Yale University School of Medicine
1985 - 1989	Principal Investigator, Gynecologic Oncology Group

Hospital and Health Care Organization Clinical Responsibilities:

1998 - 2005	Associate Director, Cancer Center, Beth Israel Deaconess Medical Center
1998 - 2005	Program Director, Gynecologic Oncology Program, Cancer Center, Beth Israel Deaconess Medical Center
1997 - 2004	Vice Chairman for Clinical Affairs, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center
1990 - 2004	Director, Division of Gynecologic Oncology, Beth Israel Deaconess Medical Center
1986 - 1990	Chief, Division of Gynecology, New England Deaconess Hospital

Major Administrative/Corporate Responsibilities:

2014 -	Vice President and Chief Medical Officer, McKesson Connected Care & Analytics
2012 - 2014	Vice President and Executive Medical Director for Population Health, McKesson Corporation
2005 - 2012	Founder MedVentive Inc. Served as Chief Executive Officer and Chief Medical Officer, Chairman of the Board of Directors, MedVentive
1999 - 2005	President, Provider Service Network (CareGroup)
2000 - 2005	Board of Directors, Affiliated Physicians Group, Beth Israel Deaconess Medical Center

- 1998 - 2000 Board of Directors, Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center
- 1998 - 2005 Board of Directors, Beth Israel Deaconess Obstetrics and Gynecology Foundation
- 1998 - 2005 Board of Directors, CareGroup Provider Services Network
- Chairman, Contracts & Finance Committee, 1998 - 2000
 - Vice-Chairman of the Board, 1999 – 2000
 - Chairman of the Board, 2000 – 2003
- 1997 - 2000 Medical Director, Obstetrics and Gynecology, Affiliated Physicians, Group, Beth Israel Deaconess Medical Center
- 1996 - 2000 Board of Directors, Beth Israel Deaconess Physicians Organization, LLC
- Chairman, Contracts and Payments Committee
 - President, 1998 – 2000
- 1995 - 1997 Clerk, Affiliated Physicians, Inc., Beth Israel Hospital

Major Committee Assignments:

National & Regional:

- 1985 - 1989 Cancer of Corpus Committee, Gynecologic Oncology Group
See Professional Society Committee positions below.

Hospital:

- 1994 - 1996 Gynecology Managed Care Committee, Beth Israel Hospital
- 1994 - 2002 Staff Council, Beth Israel Hospital
- 1995 - 1996 Wait/Delay Task Force, Beth Israel Hospital
- 1996 - 2000 Executive Committee, Women's Cancer Program, Dana-Farber Cancer Institute
- 1998 - 2000 Managed Care Steering Committee, Beth Israel Deaconess Medical Center
- Chairman, 1998 - 2000
- 1998 - 2000 Executive Committee, Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center
- 1999 - 2000 Laboratory Board, Beth Israel Deaconess Medical Center
- 1992 - 1998 Operating Room Committee, Beth Israel Deaconess Medical Center
- Chairman, 1997 - 1998
- 1991 - 2005 Cancer Committee, Beth Israel Deaconess Medical Center (& Tumor Registry Subcommittee)
- 1989 - 2005 Obstetrics and Gynecology Executive Committee, Beth Israel Deaconess Medical Center
- 1989 - 1990 Ambulatory Services Committee, New England Deaconess Hospital

- 1987 - 1995 Radiation Safety Committee, Beth Israel Hospital
- 1987 - 1990 Ambulatory Services Administrative Quality Assurance Committee, New England Deaconess Hospital
 - Chairman, 1988 - 1989
- 1987 - 1990 Surgical Case Review Committee, New England Deaconess Hospital
 - Chairman, 1989 - 1990
- 1987 - 1990 Cancer Committee, New England Deaconess Hospital
- 1985 - 1986 Cancer Committee, Brigham and Women's Hospital
- 1985 - 1986 Gyn Care Committee, Brigham and Women's Hospital
- 1982 - 1986 Cancer Committee, Boston Hospital for Women Division, Brigham and Women's Hospital
 - Recording Secretary, 1983 - 1984

Professional Society Involvement:

- 1995 - American College of Physician Executives, Member
- 1993 - American Society for Colposcopy and Cervical Pathology, Member
- 1991 - Society of Gynecologic Surgeons, Member
 - By-Laws Committee, 1996 - 1997
 - Executive Committee, 1997 - 1999
 - Research Committee, 1997 - 1999
- 1989 - Obstetrical Society of Boston, Fellow
 - Vice-President, 2007 - 2008
- 1989 - The American Society of Clinical Oncologists, Member
 - Program Committee, 1993 - 1994
- 1988 - 2014 Society of Gynecologic Oncologists, Member
- 1987 - The American College of Surgeons, Fellow
- 1987 - The New England Association of Gynecologists, Member
 - Executive Committee, 1997 - 2001
 - Chairman, Program Committee, 1999 Annual Meeting
 - President Elect, 1998 - 1999
 - President, 1999 - 2000
- 1984 - 2014 The American College of Obstetricians and Gynecologists, Fellow
- 1982 - 2008 Royal College of Surgeons of Canada, Fellow

Community Service Related to Professional Work:

1996 - 1998 Chairman, Maimonides Society, Combined Jewish Philanthropies

Editorial Boards:

2003 - Reviewer, Journal of the American Medical Association
 1994 - Reviewer, New England Journal of Medicine
 1992 - Reviewer, Cancer
 1991 - Reviewer, Plastic and Reconstructive Surgery
 1991 Reviewer, Archives in Dermatology
 1988 - Reviewer, American Journal of Obstetrics and Gynecology
 1988 - 1990 Editorial Board, Journal of Clinical Oncology
 1987 - Reviewer, Obstetrics and Gynecology
 1987 - Reviewer, European Journal of Cancer & Clinical Oncology

Awards and Honors:

2012 MedVentive awarded the **2012 Cool Vendor** designation by Gartner analysts to organizations providing innovative and potentially transformative solutions for healthcare delivery organizations

2009 MedVentive and its client, Northeast PHO (NEPHO) won the *2009 Microsoft Healthcare User Group (HUG) Interoperability Award*

2009 MedVentive was one of eight companies invited to **WellPoint's Innovation Event** showcasing its POC Registry

2006 Listed in Guide to America's Top Obstetricians and Gynecologists, 2006 Edition (Consumers Research Council of America)

2005 MedVentive won the 1st *Associated Industries of Massachusetts (AIM) Health Care Cost Containment Award* for its Pharmacy Risk Management Program

2005 MedVentive was profiled by the US DHHS for its pharmacy program as one of five national best practices for pharmacy cost management

2005 Listed in Guide to America's Top Physicians, 2004 – 2005 Edition

2005 Listed in Best Doctors in America 2005-2006 (Best Doctors, Inc.)

2005 Listed in America's Top Doctors, (Castle Connolly)

2004 Listed in America's Top Doctors, (Castle Connolly)

2003 Listed in Best Doctors 2003-2004 (Best Doctors, Inc.)

2003 Listed in America's Top Doctors, 3rd Edition (Castle Connolly)

2002 Listed in Best Doctors in America 2001-2002 (Woodward/White)

2001	Listed in America's Top Doctors (Castle Connolly)
2001	Listed in Best Doctors in America, Eighth Edition (Woodward/White)
1998	Listed in Best Doctors in America, Fourth Edition (Woodward/White)
1998	Beta Gamma Sigma Honor Society
1997	Listed in Strathmore's Who's Who
1997	Listed in Best Doctors in Boston, Boston Magazine, February, 1997
1996	Listed in Best Doctors in America in Northeast Region, 1996-1997 (Woodward/White)
1996	Listed in Marquis Who's Who in the East, 1997-1998: 26th
1995	Chief Residents Teaching Award, Beth Israel Hospital
1994	Listed in The Best Doctors in America: 1994-1995 (Woodward/White)
1984	Prize Paper Award, Obstetrical Society of Boston
1981	Clinical Project Award, American Cancer Society, Massachusetts Division
1974 - 1976	McGill University Scholar

Funding Raised

2010	Series D Funding for MedVentive Inc. Funded by Excel Venture Management, Core Capital, Clarian Health Ventures, National Healthcare Services, Ascension Health Ventures, HLM Venture Partners and Long River Ventures
2009	Series C Funding for MedVentive Inc. Funded Excel Venture Management, HLM Venture Partners and Long River Ventures.
2008	Series B Funding for MedVentive Inc. Funded by HLM Venture Partners and Long River Ventures.
2006	Series A Funding for MedVentive Inc. Funded by HLM Venture Partners and Long River Ventures.
1999 - 2000	Principal Investigator, Cervical Cancer Diagnosis by Volume Probe Telemicroscopy. Funded by MediSpectra, Inc.
1997 - 1998	Co-Principal Investigator/Subcontract, Cervical Cancer Diagnosis by Volume Probe Telemicroscopy. Funded by NIH – MediSpectra
1995 - 1997	Co-Principal Investigator/Subcontract, Cervical Cancer Diagnosis by Volume Probe Telemicroscopy. Funded by NIH – MediSpectra

Speaking Engagements

2014	June 9, 2014. <i>In Pursuit of the Triple Aim: Mining for Data</i> . Panel at The patient Centered Primary Care Collaborative. Denver.
	May 14, 2014. <i>Leading Edge or Bleeding Edge? Making Innovation Work for</i>

2013

Employers. Keynote Panel Northeast Business Group on health. New York

April 25, 2014. *Using Population health Analytics to Enact Change*. American College of Physicians Executives Spring Institute and Annual meeting. Chicago.

February 24, 2014. *You've Signed a Risk Contract; Now What?* (with Christopher Stanley, M.D.). HIMSS 2014, Orlando.

January 24, 2014. *You've Signed a Risk Contract; Now What?* American College of Physicians Executives Winter Conference. St. Petersburg

November 14, 2013. *A Prescription for Change; Strategies for Physician Engagement*. National Association of Managed Care Physicians 2013 Fall Managed Care Forum. Las Vegas

October 10, 2013. *You've Signed a Risk Contract; Now What?* HFMA Region 2 Fall Institute, Verona, NY.

September 26, 2013. *Connecting the Dots with Population Health*. InSight 2013. Orlando

August 22, 2013. *Managing the Transition from Volume to Value*, HFMA Webinar

August 6, 2013. *CHIME Data and Analytics Survey – eHI Reaction Webinar*

August 2, 2013. *Driving Down Healthcare Costs: Using Data and Analytics to Achieve Savings*. 2013 eHI National Forum on Data & Analytics. National Harbor, Maryland

May 29, 2013. *Challenges Transitioning to Accountable Care*. HFMA Webinar

May 8, 2013. *Challenges in Building a Knowledge-Based Technology Infrastructure for Population Health*. Population Health Forum. Jefferson School of Population Health. Philadelphia.

April 29, 2013. *A Prescription for Change: Strategies for Physician Engagement*. ACPE Annual Meeting. New York.

April 24, 2013. *The Role of Analytics in New Delivery Models*. New England Business Group on Health Conference. New York.

March 14, 2013. *A Prescription for Change: Strategies for Physician Engagement*. ACPE Membership Webinar.

March 3, 2013. *A Prescription for Change: Strategies for Physician Engagement*. *Leading from the Future: Delivering on Value – The Handshake Between Cost & Quality*. HIMSS. New Orleans, Louisiana

- February 23, 2013. *Accountable Care, Risk Adjustment and the Future of Allergy/Asthma Care*. Symposium 2307: Accountable Care and Population Management for the Asthma Patient in 2013 and Beyond. AAAAI Annual Meeting. San Antonio, Texas.
- January 25, 2013. *A Prescription for Change: Strategies for Physician Engagement*. ACPE. Orlando, Florida.
- 2012 January 20, 2012. *ACO Success Factors: Building a Knowledge-Based Infrastructure for Population Management*. HIMSS.
- 2011 October 2011. AHM Physician Conference: *Physician Profiling, Current Roles & Value; Ready for Prime Time?* Puerto Rico.
- October 1, 2011. *Healthcare Transformation: The Technology Factor*. North American Medical Management. Illinois.
- 2009 April 25, 2009. CMO Roundtable Discussion, Florida Roundtable Speaker on *"Managing Quality & P4P"*
- March 10, 2009. National Pay for Performance Summit, San Francisco, CA Speaker on *"Physician Efficiency Profiling"*
- 2008 Sixth Annual World Congress Leadership Summit on Healthcare Quality, Boston, MA Moderator - Best Practices Forum on *"Practical Strategies and Operational Methods to Achieve Successful Pay for Performance Implementation"*
- 2005 World Congress Leadership Summit on Healthcare Quality and Pay for Performance Contracting, Boston, MA Seminar Leader - *"Leading Case Studies on Quality Contracting with Hospitals, Group Practices, and Independent Physicians"*
- 1985 - 2004 Grand Rounds lectures in the greater Boston area and New England. Titles included:
- The CA125 Assay
 - Tumor Markers in the Management of Gynecologic Tumors
 - Management of Ovarian Cancer
 - The Role of Cytoreductive Surgery in Ovarian Cancer
 - Screening for Ovarian Cancer
 - The Management of Endometrial Cancer
 - The Management of Cervical Cancer
 - Surgical Strategies in the Managed Care Era
- 1998 University of Minnesota - Invited Lecturer, Fellows' Symposium
- 1997 Yale University School of Medicine - Invited Grand Rounds Speaker
- 1996-1997 New England Association of Gynecologists, Annual Meeting
- Moderator, Scientific sessions

- Discussion leader 1997
- 1992 Beth Israel Hospital nursing Symposium - The Care of Women with Cancer: An Integrated Approach - Ovarian Cancer: Medical/Surgical Management, Invited Lecturer
- 1992 Massachusetts Cytology Society - Colposcopy of the uterine cervix, Invited Lecturer
- 1992 Annual OB/GYN Oncology Conference, Northeastern Ohio Universities College of Medicine - Tumor Markers and the Clinical Management of Ovarian Cancer, Invited Lecturer
- 1991 Society of Gynecologic Oncologists Annual Meeting, Orlando, Invited Discussant
- 1989 The Sheila Diamond Memorial Lecture - Jewish General Hospital, McGill University, Montreal - The CA125 Assay, Invited Lecturer
- 1989 The American College of Obstetricians and Gynecologists Annual Meeting, Atlanta, GA - Plenary session - The CA125 Assay, Invited Lecturer
- 1989 Society of Gynecologic Oncologists Annual Meeting, Hawaii, Invited Discussant
- 1989 University of Rochester, Strong Memorial Hospital, Rochester, NY - The CA125 Assay, Invited Lecturer
- 1988 New England Surgical Society - The Use of Tumor Markers in Gynecologic Cancer Diagnosis and Management, Invited Lecturer
- 1985 Workshop on Clinical Applications of Monoclonal Antibodies to Cancer Diagnosis and Therapy - Tianjin Cancer Institute, Tianjin, China, Invited Lecturer
- 1984 American Cancer Society Symposium on Monoclonal Antibodies, University of Massachusetts Medical Center, Worcester, Invited Lecturer

Teaching Contributions

Local Contributions

Medical School and Hospital

- 1996 Student Advisor, Visiting Clerkship Program, Harvard Medical School
- 1993 - 1994 Lecturer, Endometrial and cervix cancer, Dana-Farber Cancer Institute Fellows Lecture Series
- 1992 - Course Director, Gynecologic Oncology (OB505M.1), Harvard Medical School
- 1986 Lecturer, Advanced Oncology for Nurses, Brigham and Women's Hospital
- 1985 - 1986 Tutor in Medical Sciences, Harvard Medical School
- 1984 - 1985 Section Leader, Reproductive Pathophysiology Course, Harvard Medical School
- 1984 - 1986 Lecturer, Core Clerkship in Obstetrics and Gynecology

- 1984 Lecture on applications of the CA125 assay, Seminars in Clinical Oncology Series, Dana-Farber Cancer Institute
- 1982 - 1985 Lectures at Gynecologic Oncology Rounds, Brigham and Women's Hospital
- 1982 - 1985 Seminars in gynecologic oncology with residents and medical students, Brigham and Women's Hospital

Graduate Medical Courses/Seminars/ Invited Presentations/ CME Courses

- 2006 HMS Center for Faculty Development – Leadership Course, Lecturer
- 2005 HMS Center for Faculty Development Course – The Business of Medicine, Lecturer
- 2005 HMS Center for Faculty Development – Leadership Course, Lecturer
- 2004 HMS Center for Faculty Development – Leadership Course, Lecturer
- 2002 Massachusetts Medical Society & the National Ovarian Cancer Coalition Symposium – Cancer in Women: A Scientific Update in Prevention, Screening Treatment and Risk Management for Ovarian and Cervical Malignancies, Lecture on screening for ovarian cancer
- 2002 Harvard Medical School CME Course – Advances in the Management of Gynecologic Cancers - Moderator
- 2000 HMS postgraduate course – Gynecology for the Nongynecologist – lecture on the management of pelvic masses
- 1994 HMS postgraduate course - Ambulatory Gynecology - lecture on screening for ovarian cancer
- 1993 HMS postgraduate course - Cancer Medicine - lectures on cervix and endometrial cancer
- 1992 HMS postgraduate course - Advanced Colposcopy - lecture on colposcopy of micro-invasive cancer of the cervix
- 1992 HMS postgraduate course - Advances in Office gynecology - lecture on screening for ovarian cancer
- 1991 - 1993 HMS postgraduate course - Colposcopy in Gynecologic Practice - lectured on the surgical management of CIN and led breakout group case discussion
- 1989 HMS postgraduate course - Medico-Legal Issues in Obstetrics and Gynecology - lecture on failure to diagnose ovarian cancer
- 1989 Boston University School of Medicine postgraduate course - lecture on cancer of the endometrium
- 1988 HMS postgraduate course - lecture on endometrial cancer
- 1988 Boston University School of Medicine postgraduate course - lecture on cancer of the vulva
- 1988 HMS postgraduate course at New England Deaconess Hospital - Cancer in Women - lectures on endometrial and ovarian cancer, Co-director of Course

- 1985 HMS postgraduate course - Cancer Medicine, lecturer
- 1984 HMS postgraduate course - Advanced Gynecologic Oncology - lecture on monoclonal antibody based assays for ovarian cancer
- 1984 HMS postgraduate course - Gynecologic Oncology - lecture on endometrial cancer
- 1984 HMS postgraduate course - Obstetrics and Gynecology - lecture on endometrial cancer

Regional, National and International Contributions

- 1995 National Advisory Council Meeting, Women's Cancer Program, DFCI, New York City - lecture on screening for cancer of the cervix
- 1984 Research Seminar, Mott Center, Wayne State University, Detroit - lecture on development and clinical applications of the CA125 assay
- 1984 American Cancer Society Symposium on Monoclonal Antibodies, University of Massachusetts Medical Center, Worcester, Invited Lecturer

Bibliography

Original Articles

- Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Van Den Berghe, Cannistra SA. *Phase I trial of Docetaxel, Carboplatin, and Gemcitabine as first-line therapy for patients with high-risk epithelial tumors of Mullerian origin.* Gynecol Oncol, 2003;89:486-493.
- Nordstrom R, Burke L, Niloff JM, Myrtle J. *The identification of cervical intraepithelial neoplasia (CIN) using UV excited fluorescence and reflectance tissue spectroscopy.* J Laser Surg Med. 2001;29:1-10.
- Collins LC, Niloff J, Burke L, Abu-Jawdeh G, Wang H. *Relative risk of high grade squamous intraepithelial lesion associated with prior abnormal Pap smears.* J. Repro Med 2001;46:105-9.
- Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. *Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.* J Clin Oncol 2000;18:2728-2732.
- Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden MV, Kim Y, Niloff J, Cannistra S. *Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.* Gynecol Oncol 2000;77:271-277.
- Rardin CR, Weisman CJ, Kim YB, Niloff JM. *Early discharge after abdominal surgery: Experience on a gynecologic oncology service.* Gynecol Oncol 1999;75:47-50.
- Burke L, Modell M, Niloff J, Kobelin M, Abu-Jawdeh G, Zelenchuk A. *Identification of squamous intraepithelial lesions: Fluorescence of cervical tissue during colposcopy.* J Lower Genital Tract Dis 1999;3:159-162.
- Flynn M, Niloff JM. *Outpatient mini-laparotomy for ovarian cysts.* J Reprod Med 1999;44:399-404.
- Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. *A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.* Obstet Gynecol 1999;93:34-7.

- Kobelin MH, Kobelin CG, Burke L, Lavin P, Niloff JM, Kim YB. *Incidence and predictors of cervical dysplasia in patients with minimally abnormal Pap smears.* *Obstet Gynecol* 1998;92:356-9.
- Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff JM, Cannistra SA. *Absence of constitutive EGF receptor activation in ovarian cancer cell lines.* *Br J Cancer* 1996;74:446-52.
- Burke L, Niloff JM, Kobelin M, Abu-Jawdeh G, Zelenchuk A, Modell M. *Use of autofluorescence of cells to evaluate cervical neoplasia.* *J Gynecol Tech* 1996;2:187-90.
- Abu-Jawdeh GM, Faix J, Niloff JM, Tognazzi K, Manseau E, Dvorak HF, Brown LF. *Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.* *Lab Invest* 1996;74:1105-15.
- McHugh M, West P, Assalty, Dupray L, Howard L, Niloff JM, Waldo K, Wandel J, Clifford J. *Establishing an interdisciplinary patient care team: Collaboration at the bedside and beyond.* *JONA* 1996;26:21-7.
- Abu-Jawdeh G, Jacobs T, Niloff JM, Cannistra SA. *Estrogen receptor is a common feature of ovarian borderline tumors.* *Gynecol Oncol* 1996;60:301-7.
- Wisner-Estin M, Niloff JM, Burke L. *Is LOOP excision overutilized in the management of high grade squamous intraepithelial lesions of the cervix?* *The Cervix and Lower Female Genital Tract* 1995;13:41-5.
- Flynn M, Niloff JM. *Minilaparotomy for the management of ovarian cysts.* *Am J Obstet Gynecol.* 1995;173:1727-30.
- Cannistra SA, Ottensmeier C, Niloff JM, Orta B, DiCarlo J. *Expression and function of beta-1 and avB3 integrins in ovarian cancer.* *Gynecol Oncol* 1995;58:216-225.
- Cannistra SA, Abu-Jawdeh G, Niloff JM, Strobel T, Swanson L, Anderson J, Ottensmeier C. *CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors.* *J Clin Oncol* 1995;13:1912-21.
- Cannistra SA, DeFranzo B, Niloff JM, Ottensmeier C. *Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.* *Clin Cancer Res* 1995;1:333-42.
- Kim YB, Ehrmann RL, Dean B, Knapp RC, Lavin P, Niloff JM. *Analysis of Pap smear screening failure in patients presenting with cervical carcinoma.* *Cervix and Lower Female Genital Tract* 1993;11:114-7.
- Cannistra SA, Kansas G, Niloff JM, DeFranzo B, Orta B, Kim Y, Ottensmeier C. *Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CCD44H.* *Cancer Res* 1993;53:3030-8.
- Tepler I, Cannistra SA, Gonon R, Anderson KC, Demetri G, Niloff JM, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Frei III E, Antman KH. *Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.* *J Clin Oncol* 1993;11:1583-91.
- Kim YB, Niloff JM. *Endometrial carcinoma: Analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and radiation therapy.* *Obstet Gynecol* 1993;82:175-80.
- Kim YB, Dubeshter B, Niloff JM. *Continuous single-layer closure of midline abdominal incisions in high-risk patients.* *J Gynecol Surg* 1992;8:15-19.

- Takayama H, Wakamiya N, O'Hara C, Arthur K, Niloff JM, Kufe D, Sakarai K, Spriggs D. *Tumor necrosis factor expression by human ovarian carcinoma in vivo*. *Cancer Res* 1991;51:4476-80.
- Shikora SA, Niloff JM, Bistran BR, Forse RA, Blackburn GL. *Relationship between obesity and uterine leiomyomata*. *Nutrition* 1991;7:251-255.
- Welch WR, Niloff JM, Taylor S, Bataile A, Anderson D, Knapp RC. *Antigenic heterogeneity in human ovarian cancer*. *Gynecol Oncol* 1990;38:12-16.
- Goodman HM, Niloff JM, Buttlar CA, Welch WR, Mark A, Feuer EJ, Lahman EA, Jenison E, Knapp RC. *Adenocarcinoma of the cervical stump*. *Gynecol Oncol* 1989;35:188-92.
- Goodman HM, Buttlar CA, Niloff JM, Welch WR, Mark A, Feuer EJ, Lahman EA, Jenison E, Knapp RC. *Adenocarcinoma of the cervix: Prognostic factors and patterns of recurrence*. *Gynecol Oncol* 1989;33:241-7.
- Loeffler JS, Rosen EM, Niloff JM, Howes AE, Knapp RC. *Whole abdominal irradiation for tumors of the uterine corpus*. *Cancer* 1988;61:1332-5.
- Niloff JM, Dubeshter B, Zurowski VR Jr, Gelman R, Hunt M, Bast RC Jr, Knapp RC. *Serum CA125 levels correlated with survival in epithelial ovarian cancer*. *Surgical Forum* 1987;38:470-2.
- Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurowski VR Jr, Bast RC Jr. *The CA125 assay as a predictor of clinical recurrence in epithelial ovarian cancer*. *Am J Obstet Gynecol*. 1986;155:56-60.
- Barbieri RL, Niloff JM, Bast RC, Schaetzel EM, Kistner RW, Knapp RC. *Elevated serum concentrations of CA125 in patients with advanced endometriosis*. *Fertil Steril*. 1986;45:630-4.
- Berek JS, Knapp RC, Malkasian GD, Lavin PT, Hacker NF, Whitney C, Niloff JM, Bast RC Jr. *Obstet Gynecol*. 1986;67:685-9.
- Niloff JM, Knapp RC, Jones G, Schaetzel EM, Bast RC Jr. *Recombinant leukocyte alpha interferon in advanced ovarian carcinoma*. *Cancer Treat Rep*. 1985;69:895-6.
- Niloff JM, Bast RC Jr, Schaetzel E, Knapp RC. *Predictive value of CA125 antigen levels in second-look procedures in ovarian cancer*. *Am J Obstet Gynecol*. 1985;151:981-6.
- Niloff JM, Knapp RC, Schaetzel E, Reynolds C, Bast RC Jr. *CA125 levels in obstetric and gynecologic patients*. *Obstet Gynecol*. 1984;64:703-7.
- Niloff JM, Klug TL, Schaetzel E, Zurowski VR, Knapp RC, Bast RC Jr. *Elevation of CA125 in carcinomas of the fallopian tube, endometrium and endocervix*. *Am J Obstet Gynecol*. 1984;148:1057-8.
- Bast RC Jr, Klug TL, Schaetzel E, Lavin P, Niloff JM, Greber TF, Zurowski VR Jr, Knapp RC. *Monitoring human ovarian cancer with a combination of CA125, CA19-9 and carcinoembryonic antigen*. *Am J Obstet Gynecol*. 1984;149:553-9.
- Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurowski VR Jr. *A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian cancer*. *Cancer Res*. 1984;44:1048-53.
- Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurowski VR, Knapp RC. *A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer*. *N Engl J Med*. 1983;309:883-7.
- Phillippe M, Niloff JM. *Metabolism of ³H-dopamine by human chorion in vitro*. *Am J Obstet Gynecol*. 1982;143:782-7.

- Niloff JM, Stubblefield PG. *Low dose vaginal 15 methyl prostaglandin F_{2α} for cervical dilation prior to vacuum curettage.* Am J Obstet Gynecol. 1982; 142:596-7.

Clinical Communications

- Lederman GS, Niloff JM, Redline R, Rosen EM. *Late recurrence in endometrial carcinoma.* Cancer 1987;59:825-8.
- Niloff JM, Knapp RC, Goldstein DP, Berkowitz RS (Contributors). *Annual report of the results of treatment in gynecologic cancer.* Vol 19, Stockholm: FIGO, 1985.
- Hornstein MD, Niloff JM, Snyder PF, Frigoletto FD. *Placenta percreta associated with a second trimester pregnancy termination.* Am J Obstet Gynecol 1984;150: 1002-3.

Reviews and Educationally Relevant Publications

- Ghosh K, Niloff JM. Vaginal bleeding. In Furie B, Cassileth PA, Atkins MB, Mayer RS, eds. *Clinical Hematology and Oncology: Presentation, Diagnosis, and Treatment.* Hong Kong: Churchill Livingstone 2003:184-190.
- Seewaldt VL, Goff BA, Greer BE, Niloff JM. *Post-therapy surveillance in patients with epithelial ovarian cancer.* In: McGuire J, Gershenson L, eds. *Ovarian Cancer: Controversies in Management.* New York: Churchill Livingstone 1998:309-23.
- Cannistra SA, Niloff JM. *Medical Progress: Cancer of the uterine cervix.* N Engl J Med 1996;33:1030-8.
- Flynn M, Niloff JM. *Mini-laparotomy for the ambulatory management of ovarian cysts (Comment).* Am J Obstet Gynecol. 1996;175:509-10.
- Niloff JM (Contributor) *Cervical cancer, Adenosquamous (Stage IB, Post simple hysterectomy).* In: Belinson JL, Markman M, eds. *Expert Consultations in Gynecologic Malignancies.* New York: Marcel Dekker, Inc. 1996:442-48.
- Niloff JM (Contributor) *Advanced borderline tumor of the ovary.* In: Belinson JL, Markman M, eds. *Expert Consultations in Gynecologic Malignancies.* New York: Marcel Dekker, Inc. 1996:305-13.
- Niloff JM, Chamberlain J. *Screening for cancer in women.* In: Sachs B, Beard R, Papiernik, Russell C, eds. *Reproductive Health Care for Women and Babies.* Oxford: Oxford University Press 1995: 101-25.
- Niloff JM. *Treatment of vaginal agenesis with vulvoperineal fasciocutaneous flaps (discussion).* Plast Reconstruct Surg 1994;93:139-40.
- Niloff JM. *Staging and operative techniques for ovarian carcinoma.* In: Daly JM, Cady B, eds. *Atlas of Surgical Oncology.* Chicago: Mosby-Year Book Inc. 1993:769-787.
- Niloff JM. *Tumor markers.* In: Hoskins WJ, Perez CA, Young RC, eds. *Principals and Practice of Gynecologic Oncology.* Philadelphia: JB Lippincott Co. 1992:137-50.
- Niloff JM, Goodman HM. *Gynecologic Oncology.* In: Steele GD, Cady B, eds. *General Surgical Oncology.* Philadelphia: WB Saunders Co. 1991:301-339.
- Niloff JM. *Ovarian malignancy.* Current Opinion in Obstet Gynecol 1991;3:66-72.

- Niloff JM. *CA125 and Tumor Markers in Gynecologic Cancer*. In: Deppe G, ed. *Chemotherapy for Gynecologic Cancer*. 2nd ed. New York: Alan R. Liss, Inc. 1990:391-408.
- Niloff JM. *Radical Hysterectomy*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc., 1988:252-3.
- Niloff JM. *Endometrial Cancer*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc., 1988:178-9.
- Niloff JM. *Carcinoma of the Cervix*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc., 1988:164-5.
- Niloff JM. *Vaginal Cancer*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc., 1988:158-9.
- Niloff JM. *Tubal Carcinoma*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc., 1988:164-5.
- Niloff JM. *Ovarian Cancer*. In: Friedman EA, Borten M, Chapin DS, eds. *Gynecological Decision Making*. 2nd ed. Philadelphia: B.C. Decker Inc. 1988:192-3.
- Niloff JM. *The role of the CA125 assay in the management of ovarian cancer*. *Oncology* 1988; 2:67-72.
- Niloff JM, Eifel P, Bloomer WD, Knapp RC. *Tumors of the corpus uteri*. In: Knapp RC, Berkowitz RS, eds. *Gynecologic Oncology*. New York: MacMillan Publishing Co., 1986:275-96.
- Bast RC Jr, Klug TL, Niloff JM, Knapp RC. *Clinical usefulness of CA125*. *Cancer Bull U Texas, MD Anderson Hospital and Tumor Institute* 1985;37:80-1.

Nonprint Materials

- Niloff JM. *Endometrial cancer*. In: Cansearch. American Cancer Society, Massachusetts Division, 1989.
- Niloff JM, Berek J, Patsner B. *CA125 - clinical applications (audiotape)*. ACOG update program, Vol 1, 1989.
- Knapp RC, Niloff JM. *Monoclonal antibodies in ovarian cancer (audiotape)*. Medical portfolio for obstetricians and gynecologists, Vol 4, 1985.

Proceedings of Meetings

Over 40 abstracts published in proceedings from scientific meetings or symposia followed by subsequent publications in peer review journals are not listed here. Additional abstracts are listed in this section.

- Berkinblit A, Tung N, Lin C, Hichey D, Catamero Y, Kim Y, Ghosh K, Niloff J, Cannistra SA. *Phase I study of Docetaxel, carboplatin, and gemcitabine (DoCaGem) as first-line therapy for patients with high-risk epithelial tumors of Mullerian origin*. Proc Am Soc Clin Oncol 2001, Vol 20:195b (2530).
- Burke L, Niloff JM, Nordstrom RJ, Myrtle JF. *The in vivo identification of cervical neoplasia using optical detection*. Proc N Engl Assoc Gynecol Oncol 2000, P 18.
- Burke L, Niloff JM, Myrtle JF. *The in vitro identification of cervical neoplasia using optical detection*. 10th World Congress of Cervical Pathology and Colposcopy. 1999 (November 11) Buenos Aires, Argentina.
- Tung N, Niloff J, Quartulli Y, Kim Y, Matulonis U, Seiden M, Berkowitz R, Lee S, Cannistra SA. *A phase I study of carboplatin, taxol, and cyclophosphamide (CTEC) with Filgrastim as first-line therapy for patients with advanced epithelial ovarian cancer*. Proc Am Soc Clin Oncol 1999, Vol 18:367a (1417).
- Collins L, Niloff J, Burke L, Abu-Jawdeh G, Wang H. *Comparison of risk of high grade squamous intraepithelial lesions (HSIL) in women with prior normal and abnormal Pap smears*. Mod Path 1999;12:42A.
- Rardin CR, Weisman CJ, Kim YB, Niloff JM. *Early discharge after major gynecologic surgery*. Proc N Engl Assoc Gynecol Oncol 1998, P26.
- Burke L, Modell M, Niloff JM, Kobelin M, Abu-Jawdeh G, Zelenchuk A. *Identification of squamous intraepithelial lesions: fluorescence of cervical tissue during colposcopy*. Am Soc Colp Cerv Path 1998.
- Zelenchuk A, Modell MD, Burke L, Niloff JM, Muchnik I. *Optical biopsy of cervix for cancer diagnosis*. Proc OSA, 1997.
- Burke L, Niloff J, Kobelin M, Modell M, Zelenchuk A. *The use of autofluorescence of cells to evaluate cervical neoplasia*. Am Soc Colp Cerv Path 1996 (Orlando).
- Wisner-Estin M, Niloff JM, Burke L. *Is LOOP excision over utilized in the management of high-grade squamous intraepithelial lesions of the cervix?* Proc N Engl Assoc Gynecol Oncol 1994.

- Wisner-Estin M, Niloff JM, Burke L. *The significance of histologically positive resection margins in patients with high grade cervical dysplasia after treatment by LOOP excision.* Proc N Engl Assoc Gynecol Oncol 1994, P. 18.
- Lentricchia B, Hutchinson M, Myer J, Sheets E, Niloff J, Lidgard G. *Discrimination of normal from precancerous exfoliated cervical cells by antibodies to nuclear matrix proteins.* Proc US and Canad Acad Path 1994, P. 39A.
- Matulonis U, Mazanet R, Niloff JM, Goodman H, Muto M, Cannistra SA. *High-dose ifosfamide, etoposide, and GM-CSF for treatment of platinum-refractory ovarian cancer: Preliminary results.* Proc Am Soc Clin Oncol 1993, Vol 12:271 (A869).
- Niloff JM, Miller LB. *Posterior thigh flap: A versatile method for the reconstruction of large defects of the vulva and perineum.* Proc N Engl Assoc Gynecol Oncol 1990: 10-11 and Proc Soc Gynecol Surg 1991.